EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer

Fortunato Cassalia iD, Andrea Danese, Ina Tudurachi, Serena Federico, Anna Zambello, Alessia Guidotti, Ludovica Franceschin, Anna Bolzon, Luigi Naldi, Anna Belloni Fortina iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25031582 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Fortunato Cassalia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preferentially Expressed Antigen in Melanoma (PRAME), a member of the cancer/testis antigen family, is central to the field of skin cancer diagnostics and therapeutics. As a nuclear receptor and transcriptional regulator, PRAME plays a critical role in inhibiting retinoic acid signalling, which is essential for cell differentiation and proliferation. Its aberrant overexpression in various malignancies, particularly cutaneous melanoma, is associated with more aggressive tumour phenotypes, positioning PRAME as both a diagnostic and prognostic marker. In melanoma, PRAME is typically highly expressed, in contrast to its weak or absent expression in benign nevi, thereby improving the accuracy of differential diagnoses. The diagnostic value of PRAME extends to various lesions. It is significantly expressed in uveal melanoma, correlating to an increased risk of metastasis. In acral melanomas, especially those with histopathological ambiguity, PRAME helps to improve diagnostic accuracy. However, its expression in spitzoid and ungual melanocytic lesions is inconsistent and requires a comprehensive approach for an accurate assessment. In soft tissue sarcomas, PRAME may be particularly helpful in differentiating melanoma from clear cell sarcoma, an important distinction due to their similar histological appearance but different treatment approaches and prognosis, or in detecting dedifferentiated and undifferentiated melanomas. In non-melanoma skin cancers such as basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma, the variable expression of PRAME can lead to diagnostic complexity. Despite these challenges, the potential of PRAME as a therapeutic target in melanoma is significant. Emerging immunotherapies, including T-cell-based therapies and vaccines targeting PRAME, are being investigated to exploit its cancer-specific expression. Ongoing research into the molecular role and mechanism of action of PRAME in skin cancer continues to open new avenues in both diagnostics and therapeutics, with the potential to transform the management of melanoma and related skin cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmMelanomaSkin NeoplasmsHumansMaleBiomarkers, TumorDiagnosis, DifferentialMelanocytesPrognosisTranscription Factors

Stichwörter der Autor:innen

NMSCPRAMESpitz tumouracral melanomamelanomamucosal melanomasoft tissue tumouruveal melanoma

Substanzen

Antigens, NeoplasmBiomarkers, TumorPRAME protein, humanTranscription Factors

Autor:innen und Institutionen

  • Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy.
  • Dermatology Unit, Department of Integrated Medical and General Activity, University of Verona, 37100 Verona, Italy.
  • Dermatology Unit, University of Magna Graecia, 88100 Catanzaro, Italy.
  • Department of Dermatology, Ospedale San Bortolo, 36100 Vicenza, Italy.
  • Centro Studi Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED), 24121 Bergamo, Italy.
  • Pediatric Dermatology Department of Women's and Child's Health (SDB), University of Padua, 35121 Padua, Italy.

ORCID-Profile: Fortunato Cassalia, Anna Belloni Fortina

Zitieren

APA

Cassalia, F., Danese, A., Tudurachi, I., Federico, S., Zambello, A., Guidotti, A., Franceschin, L., Bolzon, A., Naldi, L., & Belloni Fortina, A. (2024). PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25031582

Vancouver

Cassalia F, Danese A, Tudurachi I, Federico S, Zambello A, Guidotti A, et al. PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25031582

BibTeX
@article{Cassalia2024,
  author = {Cassalia, Fortunato and Danese, Andrea and Tudurachi, Ina and Federico, Serena and Zambello, Anna and Guidotti, Alessia and Franceschin, Ludovica and Bolzon, Anna and Naldi, Luigi and Belloni Fortina, Anna},
  title = {PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25031582}
}
Kostenlos starten →